Table 4 Incident rates and hazard ratios (HRs) for association of fracture with methotrexate and glucocorticoid use among those with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)
Variables | Number of patients | Number with fracture | Rate per 10,000 person-years (95% CI) | Unadjusted HR (95% CI) | Adjusted HR (95% CI)a |
|---|---|---|---|---|---|
PMR | |||||
Methotrexate | |||||
No | 11,430 | 1614 | 151.32 (144.11–158.89) | Reference | Reference |
Yes | 706 | 75 | 101.03 (80.57–126.69) | 0.65 (0.52–0.83) | 0.96 (0.75–1.21) |
Glucocorticoid average daily dose (quintiles) | |||||
Quintile 1 (1–4.9 mg) | 2148 | 281 | 135.72 (120.74–152.55) | Reference | Reference |
Quintile 2 (4.9–6.1 mg) | 2148 | 286 | 139.86 (124.56–157.05) | 1.03 (0.88–1.22) | 1.12 (0.95–1.32) |
Quintile 3 (6.1–7.5 mg) | 2147 | 291 | 141.52 (126.16–158.75) | 1.04 (0.88–1.23) | 1.16 (0.99–1.37) |
Quintile 4 (7.5–10.0 mg) | 2148 | 283 | 141.32 (125.78–158.78) | 1.04 (0.88–1.23) | 1.27 (1.08–1.50) |
Quintile 5 (10.0–73.3 mg) | 2147 | 367 | 196.70 (177.57–217.89) | 1.46 (1.25–1.71) | 1.85 (1.59–2.17) |
GCA | |||||
Methotrexate | |||||
No | 2551 | 353 | 147.51 (132.90–163.73) | Reference | Reference |
Yes | 122 | 18 | 140.38 (88.45–222.82) | 0.94 (0.58–1.50) | 1.36 (0.84–2.19) |
Glucocorticoid average daily dose (quintiles) | |||||
Quintile 1 (1.1–5.7 mg) | 447 | 52 | 118.06 (80.96–154.93) | Reference | Reference |
Quintile 2 (5.7–7.5 mg) | 446 | 63 | 147.64 (115.33–188.99) | 1.26 (0.87–1.81) | 1.51 (1.05–2.19) |
Quintile 3 (7.5–9.8 mg) | 447 | 59 | 138.05 (106.85–178.18) | 1.17 (0.81–1.70) | 1.46 (1.00–2.12) |
Quintile 4 (9.8–13.5 mg) | 446 | 57 | 138.33 (106.70–179.34) | 1.18 (0.81–1.71) | 1.58 (1.08–2.30) |
Quintile 5 (13.5–83.9 mg) | 446 | 72 | 181.18 (143.81–228.25) | 1.54 (1.08–2.20) | 2.09 (1.46–2.99) |